Anti-obesity medications

Anti-obesity medications has been studied in 29 papers since 2016: 6 observational studies in people, 22 reviews; 12 in the past year. It has not reached trials in people. The newest paper, Nov 2, 2026: “Risk assessment and clinical strategies of muscle loss in weight loss therapy”.

InterventionPreclinical

29 papers study it28 findingsUpdated

3 new papers in 30 daysSee all 29 papers on anti-obesity medications

At a glance

The findings reach people, from one lab or study. 8 independent labs in 3 countries.

“every 5kg weight reduction mediated by AOMs was associated with the decreased risk of all-cause mortality in patients with overweight or obesity (RR = 0.73, 95%CI, 0.59 to 0.90)”
The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled TrialsADA Scientific Sessions 2025 abstract2025doi:10.2337/db25-1730-p

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 8 independent labs in 3 countries
  • Funders: National Institutes of Health and others
  • 4 of 16 findings with company ties
  • Humans6
  • In silico1

Studies in people

3 studies gave anti-obesity medications to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on obesity-associated cancersRR = 1.03, 95% CI: 0.78 to 1.37

Review of trials40,731 people pooledPatient cohortsObesity (Silver Spring, Md.), Nov 4, 2025

down: Lowers the risk of mortalityRR 0.73 (95% CI 0.59 to 0.90)

no change: Has no effect on chronic kidney diseaseRR 0.86 (95% CI 0.58 to 1.27)

no change: Has no effect on acute kidney injuryRR 0.98 (95% CI 0.78 to 1.21)

Review of trials140,384 people pooledPer 5 kg weight reduction mediated by AOMs vs placeboADA Scientific Sessions 2025 abstract, Jun 13, 2025

no change: Has no effect on obesity-associated cancersRR 0.99, 95% CI 0.86–1.13

Review of trials90,900 people pooledBothIn patients with overweight or obesityADA Scientific Sessions 2025 abstract, Jun 13, 2025

What did studies of anti-obesity medications find?

13

Studies of anti-obesity medications measured 13 outcomes; the most studied are body weight (6 studies), muscle mass (2) and obesity-associated cancers (2).

Body weight

downin humans3downin reviews2upin reviews1

6 studies
  1. Anti-obesity medications are linked with lower body weight in humans (before seeking bariatric surgery) (-13 kg (SD 10), -4.4 kg/m2 BMI).

    “Among those who took AOMs before seeking bariatric surgery, average weight loss was 13 kg (SD 10) corresponding to a 4.4-kg/m2 decrease in BMI.”

    Humansbefore seeking bariatric surgery

    Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations

    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

  2. Anti-obesity medications decrease body weight in humans (neoadjuvant treatment before metabolic bariatric surgery).

    “Neoadjuvant AOMs can induce clinically relevant weight loss”

    Reviewneoadjuvant treatment before metabolic bariatric surgery

    Neoadjuvant and Adjuvant Anti-Obesity Pharmacotherapy as an Adjunct to Metabolic Bariatric Surgery: Current Evidence

    Polski przeglad chirurgiczny

  3. Anti-obesity medications decrease body weight.

    “Anti-obesity medications promote greater degrees of weight loss than lifestyle interventions alone.”

    Review

    Understanding Impact of Anti-Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

    Obesity reviews : an official journal of the International Association for the Study of Obesity

  4. Anti-obesity medications decrease body weight (modest effects).

    “While most approved weight loss medications have modest effects”

    Review

    Management of obesity

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

  5. Anti-obesity medications improve body weight.

    “All anti-obesity medications improve weight and metabolic parameters, with variable potency and effects depending on the specific drug.”

    Review

    Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

    EClinicalMedicine

  6. Anti-obesity medications decrease body weight in humans (around 5% more than placebo).

    “Pre-existing anti-obesity medications (AOMs) approved for long-term prescription use showed a weight reduction of around 5% more than placebo.”

    Review

    The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?

    Journal of obesity & metabolic syndrome

Muscle mass

downin humans2OR 10

2 studies
  1. Anti-obesity medications decrease muscle mass in humans.

    “Structured obesity management, including anti-obesity medications, also commonly leads to variable reductions in muscle mass with potential SO risk.”

    Review

    Sarcopenic obesity: Call to action and nutritional agenda from the international clinical nutrition community

    Clinical nutrition (Edinburgh, Scotland)

  2. Anti-obesity medications decrease muscle mass in humans (weight loss) (~6 kg or 10%).

    “This can equate to ∼6 kg or 10% of total lean mass after 12-18 mo, a loss comparable to a decade of human aging.”

    Reviewweight loss12-18 mo

    Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications

    Current developments in nutrition

Obesity-associated cancers

no changein humans2RR 0.99–1.03

2 studies
  1. Anti-obesity medications showed no clear effect on obesity-associated cancers in humans (RR = 1.03, 95% CI: 0.78 to 1.37).

    “Compared with placebo, AOMs showed no association with the risk of overall obesity-related cancer (RR = 1.03, 95% CI: 0.78 to 1.37)”

    Human trialn = 40,731

    Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials

    Obesity (Silver Spring, Md.)

  2. Anti-obesity medications showed no clear effect on obesity-associated cancers in patients with overweight or obesity (RR 0.99, 95% CI 0.86–1.13).

    “every 5 kg weight reduction mediated by AOMs was not associated with the overall risk of all 13 obesity-associated cancers in patients with overweight or obesity (RR = 0.99, 95%CI, 0.86 to 1.13)”

    Human trialin patients with overweight or obesityevery 5 kg weight reductionn = 90,900

    Weight Reduction Mediated by Antiobesity Medications and the Risk of Obesity-Associated Cancer—A Meta-analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2025 abstract

More on Obesity-associated cancers

Incident ocular outcomes

no changein humans1

1 study
  1. Anti-obesity medications showed no clear effect on incident ocular outcomes in humans (randomized controlled trials).

    “Randomized evidence identified no significant associations between any AOM and incident ocular outcomes or DR.”

    Human trialrandomized controlled trials

    Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

    Open Research (University of Surrey)

Mortality

downin humans1

1 study
  1. Anti-obesity medications decrease mortality in selected populations.

    “lower all-cause mortality in selected populations”

    Reviewin selected populations

    Anti-Obesity Medications in Longevity and Aesthetic Medicine

    Journal of clinical medicine

Major cardiovascular events

downin humans1

1 study
  1. Anti-obesity medications decrease major cardiovascular events in selected populations.

    “AOMs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations”

    Reviewin selected populations

    Anti-Obesity Medications in Longevity and Aesthetic Medicine

    Journal of clinical medicine

More on Major cardiovascular events

Dementia

no changein humans1RR 1.02

1 study
  1. Anti-obesity medications showed no clear effect on dementia in humans (randomized controlled trials versus placebo) (RR 1.02 (95% CI 0.41 to 2.54)).

    “or dementia (RR = 1.02, 95% CI 0.41 to 2.54, P = 0.97) versus placebo”

    Human trialrandomized controlled trials versus placebon = 35,924

    Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence

    Frontiers in pharmacology

More on Dementia

Cognitive disorders

no changein humans1RR 0.94

1 study
  1. Anti-obesity medications showed no clear effect on cognitive disorders in humans (randomized controlled trials versus placebo) (RR 0.94 (95% CI 0.39 to 2.25)).

    “In RCTs, the use of AOMs was not associated with a lower risk of cognitive disorder (RR = 0.94, 95% CI 0.39 to 2.25, P = 0.88)”

    Human trialrandomized controlled trials versus placebon = 35,924

    Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence

    Frontiers in pharmacology

More on Cognitive disorders

Acute kidney injury

no changein humans1RR 0.98

1 study
  1. Anti-obesity medications showed no clear effect on acute kidney injury in humans (weight reduction mediated by AOMs vs placebo) (RR 0.98 (95% CI 0.78 to 1.21)).

    “or acute kidney injury (RR = 0.98, 95%CI, 0.78 to 1.21)”

    Human trialweight reduction mediated by AOMs vs placebo

    The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2025 abstract

More on Acute kidney injury

Chronic kidney disease

no changein humans1RR 0.86

1 study
  1. Anti-obesity medications showed no clear effect on chronic kidney disease in humans (weight reduction mediated by AOMs vs placebo) (RR 0.86 (95% CI 0.58 to 1.27)).

    “the weight reduction mediated by AOMs was not associated with the risk of chronic kidney disease (RR = 0.86, 95%CI, 0.58 to 1.27)”

    Human trialweight reduction mediated by AOMs vs placebo

    The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2025 abstract

More on Chronic kidney disease

All 13

What is anti-obesity medications linked with?

8

Studies link anti-obesity medications with 8 measures, among them lifestyle interventions, mortality and colorectal cancer.

Lifestyle interventions

upin humans1

1 study
  1. Anti-obesity medications are associated with lifestyle interventions in humans (adjunct to obesity management medications in Phase 3 trials).

    “Lifestyle interventions have been core components in Phase 3 trials of FDA-approved OMMs.”

    Reviewadjunct to obesity management medications in Phase 3 trials

    A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications

    Obesity science & practice

More on Lifestyle interventions

Mortality

downin humans1RR 0.73

1 study
  1. Anti-obesity medications lower the risk of mortality in humans (per 5 kg weight reduction mediated by AOMs vs placebo) (RR 0.73 (95% CI 0.59 to 0.90)).

    “every 5kg weight reduction mediated by AOMs was associated with the decreased risk of all-cause mortality in patients with overweight or obesity (RR = 0.73, 95%CI, 0.59 to 0.90)”

    Human trialper 5 kg weight reduction mediated by AOMs vs placebo

    The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2025 abstract

Colorectal cancer

downin humans1

1 study
  1. Anti-obesity medications are linked with a lower risk of colorectal cancer in humans (aHR 0.82, 95% CI 0.71-0.96, p = 0.010).

    “colorectal (aHR: 0.82; 95% CI: 0.71-0.96; p = 0.010), and advanced-stage colorectal cancers (aHR: 0.71; 95% CI: 0.54-0.91; p < 0.001).”

    Humansfemales

    Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data

    Cancers

More on Colorectal cancer

Breast cancer

downin humans1

1 study
  1. Anti-obesity medications are linked with a lower risk of breast cancer in humans (aHR 0.84, 95% CI 0.77-0.91, p < 0.001).

    “Similar findings were observed in cancer-specific sites analysis, advanced-stage ORCs (aHR: 0.76; 95% CI: 0.65-0.89; p < 0.001), breast (aHR: 0.84; 95% CI: 0.77-0.91; p < 0.001)”

    Humansfemales

    Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data

    Cancers

More on Breast cancer

Obesity-related cancer

downin humans1

1 study
  1. Anti-obesity medications are linked with a lower risk of obesity-related cancer in humans (aHR 0.78, 95% CI 0.73-0.84, p < 0.001).

    “We found an inverse association between the use of AOMs and the risk of ORCs (aHR: 0.78; 95% CI: 0.73-0.84; p < 0.001).”

    Humansfemales

    Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data

    Cancers

More on Obesity-related cancer

Gastrointestinal side effects

upin humans1

1 study
  1. Anti-obesity medications are associated with gastrointestinal side effects in humans (reported in 32.2% of patients across studies).

    “Gastrointestinal side effects were reported in 32.2% of patients across studies.”

    Review

    Clinical studies on anti-obesity medications in Arab countries

    Saudi medical journal

Osteoarthritis

downin humans1

1 study
  1. Anti-obesity medications are linked with a lower risk of osteoarthritis in humans.

    “The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01).”

    HumansAOM users compared with non-users, propensity-score matched and adjusted for comorbidities and sociodemographic factors6-month follow-up

    The impact of approved anti-obesity medications on osteoarthritis

    Expert opinion on pharmacotherapy

More on Osteoarthritis

Periprocedural aspiration

upin reviews1

1 study
  1. Anti-obesity medications raise the risk of periprocedural aspiration (periprocedural setting).

    “altered gastrointestinal motility and risk for periprocedural aspiration”

    Reviewperiprocedural setting

    Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks

    Alimentary pharmacology & therapeutics

More on Periprocedural aspiration

Funding

3 grants since 2023

National Institute of Diabetes and Digestive and Kidney Diseases$1.7MNational Heart, Lung, and Blood Institute$1.5M

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 1Sep 2026: 2Oct 2026: 1Nov 2026: 111 papers in 12 months

See all 29 papers on anti-obesity medications